(Q42605756)

3 November 2017

title

Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months (English)

1 reference

3 November 2017

1 reference

1

1 reference

3 November 2017

5

1 reference

3 November 2017

Josep-María Cendrós

2

1 reference

3 November 2017

Concepción Peraire

3

1 reference

3 November 2017

Joaquim Ramis

4

1 reference

3 November 2017

Paolo F Boscani

6

1 reference

3 November 2017

Rosendo Obach

7

1 reference

3 November 2017

publication date

1 January 2009

1 reference

Clinical Pharmacokinetics

3 November 2017

published in

1 reference

3 November 2017

volume

48

1 reference

3 November 2017

issue

1

1 reference

3 November 2017

page(s)

51-62

1 reference

Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.

3 November 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F0003088-200948010-00004

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel

21 January 2018

1 reference

12 December 2020

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial

1 reference

12 December 2020

Self-association process of a peptide in solution: from beta-sheet filaments to large embedded nanotubes

1 reference

12 December 2020

The use of Weibull distribution to describe the in vivo absorption kinetics

1 reference

12 December 2020

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

1 reference

12 December 2020

Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days

1 reference

12 December 2020

Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension

1 reference

12 December 2020

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration

1 reference

12 December 2020

Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil

1 reference

12 December 2020

Somatuline Autogel: an extended release lanreotide formulation.

1 reference

12 December 2020

Clinical results of long-term slow-release lanreotide treatment of acromegaly

1 reference

12 December 2020

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

1 reference

12 December 2020

Results of a two-year treatment with slow release lanreotide in acromegaly

1 reference

12 December 2020

Ways to fit a PK model with some data below the quantification limit

1 reference

12 December 2020

Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection.

1 reference

12 December 2020

Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition.

1 reference

12 December 2020

Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency

1 reference

12 December 2020

Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel

1 reference

12 December 2020

10.2165/0003088-200948010-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

3 November 2017

1019732889

0 references

1 reference